| __timestamp | Takeda Pharmaceutical Company Limited | Veracyte, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 520990000000 | 16606000 |
| Thursday, January 1, 2015 | 535405000000 | 21497000 |
| Friday, January 1, 2016 | 558755000000 | 25462000 |
| Sunday, January 1, 2017 | 495921000000 | 28195000 |
| Monday, January 1, 2018 | 659690000000 | 33078000 |
| Tuesday, January 1, 2019 | 1089764000000 | 36523000 |
| Wednesday, January 1, 2020 | 994308000000 | 41455000 |
| Friday, January 1, 2021 | 1106846000000 | 74400000 |
| Saturday, January 1, 2022 | 1244072000000 | 101582000 |
| Sunday, January 1, 2023 | 1431505000000 | 112903000 |
| Monday, January 1, 2024 | 1431505000000 |
Unleashing insights
In the ever-evolving pharmaceutical and biotech sectors, understanding cost structures is crucial. Takeda Pharmaceutical Company Limited, a global leader, and Veracyte, Inc., a rising star in genomic diagnostics, present a fascinating contrast in their cost of revenue trends from 2014 to 2023. Takeda's cost of revenue has surged by approximately 175% over this period, reflecting its expansive growth and strategic acquisitions. In contrast, Veracyte's cost of revenue, though significantly smaller, has increased by nearly 580%, highlighting its rapid scaling and innovation-driven approach. Notably, Takeda's costs peaked in 2023, while Veracyte's data for 2024 remains elusive, suggesting potential shifts in their financial strategies. This comparison underscores the diverse financial landscapes within the healthcare industry, where established giants and agile newcomers navigate their paths to success.
Cost of Revenue Comparison: Pfizer Inc. vs Takeda Pharmaceutical Company Limited
Cost of Revenue: Key Insights for Pfizer Inc. and Veracyte, Inc.
Comparing Cost of Revenue Efficiency: Takeda Pharmaceutical Company Limited vs Walgreens Boots Alliance, Inc.
Cost of Revenue Comparison: Takeda Pharmaceutical Company Limited vs CRISPR Therapeutics AG
Comparing Cost of Revenue Efficiency: Takeda Pharmaceutical Company Limited vs Amneal Pharmaceuticals, Inc.
Cost of Revenue Trends: Takeda Pharmaceutical Company Limited vs Ligand Pharmaceuticals Incorporated
Takeda Pharmaceutical Company Limited vs Supernus Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down BioMarin Pharmaceutical Inc. and Veracyte, Inc.'s Expenses
Cost Insights: Breaking Down Cytokinetics, Incorporated and Veracyte, Inc.'s Expenses
Cost Insights: Breaking Down Perrigo Company plc and Veracyte, Inc.'s Expenses
Cost of Revenue: Key Insights for Veracyte, Inc. and ACADIA Pharmaceuticals Inc.
Cost of Revenue: Key Insights for Veracyte, Inc. and Mesoblast Limited